Progressive Supranuclear Palsy (PSP) is a progressive neurodegenerative disease that affects approximately 5 people per 100,000 of the UK population. Sometimes initially misdiagnosed as Parkinson's disease, PSP frequently presents with slowness of movement and thought, as well as falls (typically backwards). There may be early problems with speech and swallowing.
Drugs used to treat Parkinson's disease are usually ineffective in PSP. Our understanding of the underlying pathological processes in PSP has advanced significantly in recent years and this is translating into clinical trials of novel drugs.